Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG

vaccination

Authors:

Juana Claus MSc¹ (https://orcid.org/0000-0002-2258-3900) Thijs ten Doesschate PhD^{1,2} (https://orcid.org/0000-0002-2965-9998) Esther Taks MD³ Priya Debisarun MD³ (https://orcid.org/0000-0003-3171-3903) Gaby Smits MSc⁴ Rob van Binnendijk PhD⁴ (https://orcid.org/0000-0002-5808-1443) Fiona van der Klis PhD⁴ (https://orcid.org/0000-0002-6759-3539) Lilly M. Verhagen PhD^{5,6} (https://orcid.org/0000-0002-3451-9201) Marien I. de Jonge PhD⁶ (https://orcid.org/0000-0003-2812-5895) Marc J.M. Bonten PhD¹ (https://orcid.org/0000-0003-29095-9201) Mihai G. Netea PhD^{3,7} (https://orcid.org/0000-0003-2421-6052) Janneke H. H. M. van de Wijgert PhD^{1,4*} (https://orcid.org/0000-0003-2728-4560), corresponding author

Affiliations:

- 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
- 2. Current affiliation: Department of Internal Medicine, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Netherlands
- 3. Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
- 4. National Institute of Public Health and the Environment, Bilthoven, Netherlands
- 5. Department of Paediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, Netherlands
- 6. Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands
- 7. Department for Genomics & Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Germany

*Corresponding Author:

Janneke van de Wijgert Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Universiteitsweg 100, 3584 CG Utrecht Email: j.h.h.vandewijgert@umcutrecht.nl

Keywords: SARS-CoV-2, COVID-19, serology, infection, vaccination, BCG

Word counts:

Abstract/Summary: 196 Main text: 4017 References: 40 Number of tables and figures: 5 Supplements: 1

1 Summary

2	SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins;
3	COVID-19 vaccines against the S-protein only. The BCG-Corona trial, initiated in March 2020 in SARS-
4	CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks and the introduction of
5	COVID-19 vaccines during the one-year follow-up. We assessed determinants of systemic anti-S1 and
6	anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomized to BCG
7	or placebo vaccination, reported daily symptoms, SARS-CoV-2 test results, and COVID-19
8	vaccinations, and donated blood for SARS-CoV-2 serology at two time points. In the 970 participants,
9	anti-S1 geometric mean antibody concentrations (GMCs) were much higher than anti-N GMCs. Anti-
10	S1 GMCs significantly increased with increasing number of immune events (SARS-CoV-2 infection or
11	COVID-19 vaccination): 104.7 international units (IU)/ml, 955.0 IU/ml, and 2290.9 IU/ml for one, two,
12	and three immune events, respectively (p<0.001). In adjusted multivariable linear regression models,
13	anti-S1 and anti-N \log_{10} concentrations were significantly associated with infection severity, and anti-
14	S1 log ₁₀ concentration with COVID-19 vaccine type/dose. In univariable models, anti-N log ₁₀
15	concentration was also significantly associated with acute infection duration, and severity and
16	duration of individual symptoms. Antibody concentrations were not associated with Long COVID or
17	long-term loss of smell/taste.

18 Introduction

19	The systemic humoral immune response to SARS-CoV-2 is characterized by antigen-specific
20	antibodies, which play a crucial role in host defence and protection against re-infection. Following an
21	infection, systemic immunoglobulins type G (IgG) specific to SARS-CoV-2, including antibodies against
22	the viral spike (S) and nucleocapsid (N) proteins, are detected in the majority of patients within two
23	weeks, with peak concentrations at around three weeks after symptom onset [1–3]. While natural
24	infection typically gives rise to both anti-S and anti-N antibodies, the COVID-19 vaccines that were
25	authorized in the European Union within the first two years of the epidemic (mRNA [4, 5] and viral
26	vector vaccines[6, 7]) were engineered to elicit an anti-Simmune response only [3]. The presence of
27	anti-S antibodies is a more sensitive and specific marker for the presence of a SARS-CoV-2 infection
28	than the presence of anti-N antibodies[8], with a reported sensitivity of 91.3-97.1% (depending on
29	infection severity) and specificity of 98.1% [9]. Anti-N sensitivities are estimated to be 85% for mild
30	infections and 67% for asymptomatic infections, and specificity 97% (96%-98%) [10].
31	
32	The S-protein, containing the S1 subunit with the receptor binding domain, is abundant and readily
33	accessible on the viral surface. Conversely, the N-protein resides within the core of the viral structure
34	and is less exposed to the host immune system [3]. Furthermore, the N-protein is highly conserved
35	among the different coronaviruses, including some common cold-causing coronaviruses that
36	circulate widely, and existing immunity to anti-N is therefore present in most populations [11, 12].
37	However, anti-N is the only biomarker currently available to detect recent natural infections in a

39

38 vaccinated population [10].

Studies have suggested that antibody concentrations over time likely vary by numbers, types, and
combinations of immune events (SARS-CoV-2 infections or COVID-19 vaccinations), disease severity,
and other virus, host, and vaccine characteristics [13–16]. However, asymptomatic and very mild
cases in relatively healthy hosts were underrepresented in studies thus far, with most research

Version 22 January 2024

44	focused on the broad WHO-defined mild, moderate, and severe infections [17]. We therefore used
45	data from our previously published BCG-Corona trial in healthy healthcare workers [18, 19] to assess
46	systemic anti-S1 IgG and anti-N IgG responses at the end of the first year of the SARS-CoV-2 epidemic
47	in the Netherlands. Previous BCG-Corona trial analyses found that baseline BCG vaccination did not
48	reduce SARS-CoV-2 infection incidence, duration, or severity, nor SARS-CoV-2 antibody responses, in
49	the first year after vaccination [19]. In this paper, our aim was to assess whether numbers, types, and
50	combinations of immune events, SARS-CoV-2 infection severity and duration, and participant
51	characteristics (including having received BCG or placebo vaccination at baseline) were associated
52	with systemic SARS-CoV-2-specific antibody concentrations after one year of follow-up. The strengths
53	of these analyses include coverage of the first year of the epidemic when participants were still
54	immunologically naïve for SARS-CoV-2 and the completeness of the dataset. BCG-Corona study
55	participants reported symptoms daily, and positive SARS-CoV-2 test results, healthcare seeking
56	behaviour, and vaccinations weekly, and donated blood samples for serology twice in one year. This
57	comprehensive data enabled us to characterize infections, including asymptomatic and very mild
58	infections, in great detail.
59	

60 Methods

61 Study design and participants

62 The BCG-Corona trial was a multi-centre, double-blind, placebo-controlled randomized trial. The study 63 protocol was approved by the institutional review board of the University Medical Center Utrecht, the 64 Netherlands, and, registered at clinicaltrials.gov (identifier: NCT04328441).[20] The trial protocol and 65 primary results of the trial have been published [18, 19]. Healthcare workers from nine Dutch hospitals 66 who were expected to be in direct contact with COVID-19 patients were vaccinated with BCG or 67 placebo vaccine (1:1) during the first SARS-CoV-2 epidemic wave in March/April 2020 and followed up 68 for about one year. The participating study sites were categorized into core hospitals (N=3) that 69 implemented on-site venepuncture sampling, and other hospitals (N=6) that implemented at-home

70 fingerprick sampling (full eligibility criteria and sampling procedures in Supplementary Material,

71 available on the Cambridge Core website).

72

73 Data collection and seroconversion periods

74 Participants were invited to donate a blood sample at two time points during follow-up. This divided 75 the follow-up time into two potential seroconversion periods. The first seroconversion period started 76 on the date of randomisation until the date of the first sampling round, about three months (M3) 77 following BCG/placebo vaccination for the core hospitals and about six months (M6) for the other 78 hospitals. The second seroconversion period was between the first sampling round and the second 79 sampling round, approximately 12 months (M12) after BCG/placebo vaccination for all hospitals. 80 Total follow-up time for each participant was the number of days between randomisation and the 81 date of M12 sampling. Baseline characteristics were entered into an online questionnaire by study 82 staff at the time of randomisation (Research Online, Julius Center, UMC Utrecht, the Netherlands). 83 Participants were instructed to report daily symptoms including their severity using a smartphone 84 diary application (Research Follow App, Your Research BV, Huizen, Netherlands) as well as the dates 85 and results of any SARS-CoV-2 test, any other healthcare seeking behaviour, and any vaccination 86 (Supplementary Methods).

87

88 COVID-19 vaccinations

89 COVID-19 vaccine roll-out in the Netherlands began on 6 January 2021, and the diary app was

90 updated with weekly questions about the date(s) and types of COVID-19 vaccinations at this time.

91 The COVID-19 vaccines available during the study period were the mRNA vaccines Spikevax

92 (Moderna Biotech, Cambridge, MA, USA) and Comirnaty (Pfizer/BioNTech, New York, NY, USA), and

93 the vector vaccines Vaxzevria (AstraZeneca AB, Sodertalje, Sweden) and Jcovden (Janssen Vaccines,

Leiden, Netherlands). By the time the M12 blood sampling was completed in June 2021, healthcare

95 workers could have received zero, one or two doses of only one vaccine type.

Version 22 January 2024

96

97 Antibody measurements

98	All systemic antibody testing was conducted by the Center for Immunology of Infections and
99	Vaccines at the National Institute for Public Health and the Environment in Bilthoven, the
100	Netherlands. In the first seroconversion period, prior to the start of the COVID-19 vaccination
101	campaign, only anti-S1 IgG antibodies were assessed. At M12, both anti-S1 and anti-N IgG antibodies
102	were assessed to enable differentiation between natural infections and vaccine-induced antibodies.
103	Anti-S1 and anti-N concentrations were measured using an in-house magnetic immunoassay on a
104	Luminex platform, with reported sensitivities of 91.3-97.1% and 67-85% (depending on infection
105	severity) for anti-S1 and anti-N respectively, and specificities of 98.1% and 97%, respectively [9, 10].
106	Anti-S1 and anti-N concentrations were measured simultaneously if applicable. The concentrations
107	were subsequently calibrated against the international standard for human anti-SARS-CoV-2
108	immunoglobulin (20/136 NIBSC standard [21]) and expressed as international units per mL
109	(IU/mL)[10, 22]. The threshold for seropositivity was set to 10.1 IU/mL for anti-S1 and 14.3 IU/mL for
110	anti-N. Samples that were below these thresholds were considered to have concentrations of zero.
111	The anti-S1 and anti-N concentrations displayed gamma distributions and were \log_{10} transformed
112	after adding a pseudocount of +1 to each value to eliminate zero values (Figure S1). We focused the
113	analyses on the M12 antibody concentrations, because most immune events took place between the
114	first (M3/M6) and second (M12) sampling rounds.

115

116 Definitions of antibody concentration determinants

A single immune event was defined as one SARS-CoV-2 infection episode or one dose of a COVID-19 vaccine. An infection episode was defined as a positive test (PCR or rapid antigen test) reported by the participant and/or evidence of seroconversion (for anti-S1 in the first seroconversion period and anti-S1 plus anti-N in the second seroconversion period). We also categorized participants by the vaccination types and doses that they received, and immunity type: natural immunity, vaccine

Version 22 January 2024

immunity (after one or two doses), or hybrid immunity (a combination of natural infection and oneor two vaccine doses).

124

125	To determine infection severity, we matched each infection episode with corresponding self-
126	reported symptoms and healthcare seeking behaviour information (Supplementary Methods). We
127	subsequently categorized each infection episode in accordance with World Health Organisation
128	(WHO) severity categories of asymptomatic, mild, moderate and severe [17]. However, only three
129	BCG-Corona participants were hospitalized (WHO moderate category), and all other symptomatic
130	episodes qualified as WHO mild. We therefore further subdivided the WHO mild category into very
131	mild and mild subcategories (Supplementary Methods): mild episodes were accompanied by more
132	severe respiratory symptoms and/or fever, and lasted longer, compared to very mild episodes. The
133	duration of the acute phase of the infection episode was defined as the number of consecutive days
134	during which the participant reported symptoms, not including standalone loss of smell/taste. Long-
135	term loss of smell/taste and Long COVID (lingering symptoms other than standalone loss of
136	smell/taste) were defined as continuing to report the respective symptoms for at least 60 days after
137	the end of the acute infection episode. Duration of episodes that were ongoing at the end of follow-
138	up were coded as unknown. Chronic symptoms that were reported regularly throughout follow-up
139	were ignored.
140	

141 Statistical analyses

142 Statistical analyses were performed in R version 4.2.2 (PBC, Boston, MA, USA). Participants were

excluded from the analysis population if they did not donate a M12 sample, their infection status was

- 144 unsure, or their sample was taken in a seroconversion window after infection or vaccination.
- 145 Infection status was considered unsure if a participant never reported a positive test but had
- 146 completed less than 80% of diary entries, or had anti-N but no anti-S1 antibodies at M12. The
- seroconversion window was defined as 14 days, but sensitivity analyses were conducted using 7 and

Version 22 January 2024

148 0 days. Participants who were in the seroconversion window for the second dose of a COVID-19

149 vaccine were included as having received only one dose.

150

151	Characteristics between groups were compared using Chi-squared test for categorical variables and
152	Wilcoxon rank sum test for continuous variables. The antilog 10 ^x of mean concentrations was taken
153	to obtain geometric mean concentrations (GMCs). Mean log10-transformed antibody concentrations
154	between groups were compared using Kruskal-Wallis tests. Associations between covariates (with
155	categorical variables analysed as indicator variables) and log10-transformed anti-S1 and anti-N
156	concentrations at M12 were assessed using linear regression models. BCG versus placebo vaccination
157	at baseline, age, and sex were forced into each multivariable model. Other covariates were
158	considered for inclusion in multivariable models based on statistical significance in univariable linear
159	regression, using p<0.05 as the cut-off value. To avoid multicollinearity, we included combination
160	variables for COVID-19 vaccination (number of doses received plus vaccine product if at least one
161	dose received) and overall infection severity (whether an infection took place and if yes, its overall
162	severity based on both symptom severity and duration), but not number of immune events, overall
163	acute infection episode duration, or severity/duration of individual symptoms.
164	
165	Results

166 Participant characteristics

The analysis population consisted of 970 of the 1511 randomized participants (Figure 1). Baseline characteristics were comparable between the two populations, and between the BCG and placebo groups within each population (Table 1A) [19]. The majority of the participants (74.7%) were female, with a mean age of 42.5 years (range 18-67), and had high (60%) to medium risk (24.7%) of workrelated SARS-CoV-2 exposure (Supplementary Methods). The prevalence of chronic comorbidities other than hay fever was low. As expected, immune event-related characteristics during follow-up differed between the analysis and randomized populations (Table 1B) because application of the 14-

day seroconversion window resulted in the removal of some immune events from the analysis

175 population (Figure S2; Table S1).

176

177 M12 anti-S1 and anti-N IgG GMCs by immune events

178	The M12 anti-S1 and anti-N GMCs did not differ between the BCG and placebo groups (Table 2,
179	Figures 2A-B), also not after stratification by number of immune events or immunity type (Figure S3).
180	About half of the participants (517; 53.3%) experienced an immune event during follow up: 187
181	(19.3%) experienced one, 260 (26.8%) two, and 70 (7.2%) three immune events (Table 1B). About
182	two thirds (65.8%) of the participants who experienced one immune event had an infection and
183	34.2% received one dose of a COVID-19 vaccine; 11.5% of the participants who experienced two
184	immune events had an infection plus received one dose of a COVID-19 vaccine, while 88.5% received
185	two doses of a COVID-19 vaccine. All participants with three immune events had an infection plus
186	received two doses of a COVID-19 vaccine. M12 anti-S1 GMCs were higher with increasing number of
187	immune events: 104.7 IU/ml (standard deviation (SD)=7.2) for one, 955.0 IU/ml (SD=4.1) for two, and
188	2290.9 IU/ml (SD=2.6) for three immune events (p<0.001; Table 2, Figures 2C+E). The M12 anti-S1
189	GMC was higher after one COVID-19 vaccine dose compared to after one infection: 177.8 IU/ml
190	(SD=7.59) and 79.4 IU/ml (SD=6.61), respectively (p=0.010). The M12 anti-N GMC increased after
191	infection but not after vaccination(s) as expected (Table 2, Figures 2D+F), and was lower than the
192	anti-S1 GMC after infection: 26.3 IU/ml (SD=4.5) compared to 79.4 IU/ml (SD=6.6), respectively
193	(p<0.001). M12 anti-S1 and anti-N \log_{10} concentrations by time since an immune event showed
194	considerable inter-individual variability but not a general downward trend, suggesting the follow-up
195	period was not long enough for antibody waning (Figure S4).

196

197 M12 anti-S1 and anti-N IgG GMCs by COVID-19 vaccinations

198 Of the 394/970 (40.6%) participants who received COVID-19 vaccination during follow-up, 94/970

199 (9.7%) received one dose and 300/970 (30.9%) received two doses. The majority (355/394; 90.1%)

Version 22 January 2024

200	received an mRNA vaccine (305 Comirnaty, 49 Spikevax, and one an experimental vaccine by CureVac
201	N.V. in a clinical trial setting), 36/394 (9.1%) received a viral vector vaccine (32 Vaxzevria and 4
202	Jcovden), and for three (0.8%) information on the vaccine type was missing (Table 1B). It should be
203	noted that all participants who received two vaccine doses received mRNA vaccines, while those who
204	received one dose received either a first dose of a mRNA vaccine (58.5%), a first or only dose of a
205	vector vaccine (38.3%), or unknown vaccine type (3.2%). When excluding all participants who
206	experienced an infection, M12 anti-S1 GMCs were significantly higher in participants who had
207	received one dose of a mRNA vaccine (467.7 IU/ml; SD=5.8) compared to one dose of a viral vector
208	vaccine (63.1 IU/ml; SD=5.0; p<0.001; Table 2, Figures 2G-I). Two doses of a mRNA vaccine resulted in
209	a higher anti-S1 GMC than one (Table 2). M12 anti-S1 concentrations were higher in the Spikevax
210	compared to the Comirnaty group; 562.3 IU/ml (SD=5.6) and 120.2 IU/ml (SD=4.6) for a single dose of
211	Spikevax and Comirnaty, respectively (p=0.165), and 1230.2 IU/ml (SD=2.1) and 794.33 IU/ml
212	(SD=3.5) for two doses of Spikevax and Comirnaty, respectively (p=0.583; Table S2). M12 anti-S1
213	GMCs were highest in participants who had an infection and also received one or two COVID-19
214	vaccinations: 3981.07 IU/ml (SD=5.37) and 2290.87 IU/ml (SD=2.63), respectively (Table 2).
215	
216	M12 anti-S1 and anti-N IgG GMCs by SARS-CoV-2 infections
217	A total of 223 first infections occurred in the analysis population during follow-up: 33 (14.8%) were
218	asymptomatic, 120 (53.8%) very mild, 44 (19.7%) mild, 2 (0.90%) moderate, and 24 (10.8%) of
219	unknown severity. Among those who experienced an infection during follow-up, 30/223 (13.5%)
220	received one COVID-19 vaccine dose and 70/223 (31.4%) received two doses. The M12 anti-S1 GMCs
221	did not statistically significantly differ by overall infection severity when analysed as an ordinal
222	variable (p=0.566), and this remained the case after stratifying by the number of COVID-19 vaccine
223	doses received (Table 2, Figures 2J-K). In contrast, the M12 anti-N GMCs significantly increased with
224	increasing overall infection severity: 13.8 IU/ml (SD=3.1) for asymptomatic, 22.9 IU/ml (SD=4.6) for

very mild, 44.7 IU/ml (SD=3.3) for mild, and 45.7 IU/ml (SD=25.7) for moderate infections (p=0.002;

Version 22 January 2024

226	Table 2, Figures 2L-M). The M12 anti-S1 and anti-N GMCs were not associated with increasing acute
227	episode duration, Long COVID or long-term loss of smell/taste (Table 2, Figures S5A-F). M12 anti-S1
228	GMCs were not associated with the severity or duration of specific individual symptoms (analysed as
229	ordinal variables) either. In contrast, M12 anti-N GMCs were higher with higher severity and longer
230	duration of respiratory symptoms excluding dyspnoea, with the presence and duration of fever, and
231	with the severity of non-respiratory symptoms other than fever (Table 2, Figures S5G-T). Of note, the
232	severity and duration of dyspnoea were not associated with either M12 anti-S1 or M12 anti-N GMCs
233	(Table 2, Figure S5G-J).
234	
235	The M12 anti-S1 and anti-N GMCs of participant who experienced an infection were correlated at the
236	individual level: participants with a higher M12 anti-S1 GMC also had a higher M12 anti-N GMC
237	(Figure S6). This correlation was most pronounced for those who never received a COVID-19 vaccine
238	during follow-up (Spearman's ρ =0.69; p<0.001) and weakened in participants who had received one
239	(ρ =0.54; p=0.003) or two vaccinations (ρ =0.32; p=0.006) that boosted anti-S1 GMCs only.
240	
241	Linear regression models of M12 anti-S1 and anti-N concentrations
242	In universable models including the entire analysis population (N=970), the number of immune
	In univariable models including the entire analysis population (N=970), the number of infinute
243	events, immune event type, overall infection severity (analysed as an indicator variable), and work-
243 244	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀
243 244 245	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only
243 244 245 246	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only associated with M12 anti-S1 log ₁₀ concentration, while hypertensive medication use and history of
243 244 245 246 247	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only associated with M12 anti-S1 log ₁₀ concentration, while hypertensive medication use and history of pulmonary disease other than asthma and hay fever were only associated with M12 anti-N log ₁₀
243 244 245 246 247 248	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only associated with M12 anti-S1 log ₁₀ concentration, while hypertensive medication use and history of pulmonary disease other than asthma and hay fever were only associated with M12 anti-N log ₁₀ concentrations. BCG/placebo vaccination at baseline, age, sex, smoking, history of BCG vaccination,
243 244 245 246 247 248 249	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only associated with M12 anti-S1 log ₁₀ concentration, while hypertensive medication use and history of pulmonary disease other than asthma and hay fever were only associated with M12 anti-N log ₁₀ concentrations. BCG/placebo vaccination at baseline, age, sex, smoking, history of BCG vaccination, influenza vaccination during follow-up, recent respiratory tract infections, and the comorbidities that
243 244 245 246 247 248 249 250	events, immune event type, overall infection severity (analysed as an indicator variable), and work- related exposure risk were statistically significantly associated with both M12 anti-S1 and anti-N log ₁₀ concentrations (Table S3A). Vaccine doses and types (combined into one variable) were only associated with M12 anti-S1 log ₁₀ concentration, while hypertensive medication use and history of pulmonary disease other than asthma and hay fever were only associated with M12 anti-N log ₁₀ concentrations. BCG/placebo vaccination at baseline, age, sex, smoking, history of BCG vaccination, influenza vaccination during follow-up, recent respiratory tract infections, and the comorbidities that were not already mentioned were not associated with M12 anti-N log ₁₀ concentrations

252 (n=223), overall infection severity, overall acute episode duration, and specific symptom severity and 253 duration, with the exception of dyspnoea, were significantly associated with M12 anti-N \log_{10} 254 concentrations (all as indicator variables; Table S3B). Long COVID and long-term loss of smell/taste 255 were not associated with M12 anti-S1 or anti-N log₁₀ concentrations in individuals who had 256 experienced an infection. 257 258 The final multivariable models with M12 anti-S1 or anti-N log₁₀ concentrations as the outcomes and 259 BCG/placebo vaccination at baseline, age, and sex forced into the models are shown in Table 3. Age, 260 vaccine type plus dose (indicator variable), and overall infection severity (indicator variable) were 261 statistically significantly associated with M12 anti-S1 log₁₀ concentration. Sex and overall infection 262 severity (indicator variable) were associated with M12 anti-N log₁₀ concentration. Current use of 263 hypertensive medication was associated with M12 anti-N log₁₀ concentration in univariable analysis 264 but was no longer significant in the multivariable model. Sensitivity analyses adding more covariates 265 (Figure S7), or reducing the seroconversion windows to 7 and 0 days (Table S4), produced similar 266 results with two exceptions. The positive associations between M12 anti-S1 log₁₀ concentration and 267 mild or moderate infection severity (compared to no infection) and having received one dose of a 268 mRNA or vector vaccine (compared to no vaccination) changed in magnitude, but remained 269 statistically significant, when the seroconversion period was reduced to 7 or 0 days (Table S4; 270 Supplementary Results). 271

272 Discussion

SARS-CoV-2 anti-S1 and anti-N GMCs approximately one year after the start of the Dutch SARS-CoV-2
epidemic were associated with the number of immune events, and overall infection severity when an
infection took place, but not with having had or having Long COVID or long-term loss of smell/taste.
Anti-S1 GMCs were also associated with COVID-19 vaccination, and anti-N GMCs with specific
symptom severity and duration except for dyspnoea. Anti-S1 GMCs were higher after one vaccination

than one infection, and after one mRNA than one vector vaccination, and highest after a combinationof infection and vaccination(s).

280

281	Our finding of higher anti-S1 GMCs with an increasing number of immune events, and after
282	vaccination with mRNA compared to vector vaccines, is in agreement with the published literature
283	[23-25]. However, published reports for infection versus vaccination are inconsistent [26]. Important
284	variables in that context are the severity and duration of infections, waning antibody concentrations
285	over time, and the timing of boosting events. We were able to investigate the former, but not the
286	latter. We did not detect a downward trend of antibody GMCs by time period between the last
287	immune event and M12 sampling, but we could not evaluate antibody concentrations longitudinally
288	for individual participants due to the low number of immune events in the first seroconversion
289	period. The COVID-19 vaccination campaign in the Netherlands began eight months after the start of
290	the study and SARS-CoV-2 infections took place throughout follow-up. Our finding of higher anti-S1
291	GMC after one vaccination than after one infection could therefore be explained by the timing of
292	immune events and subsequent waning antibody concentrations over time. However, the follow-up
293	time was short with little opportunity for waning, and our findings were robust after applying
294	seroconversion windows of 14, 7 or 0 days. Another potential explanation is lower antigen exposure
295	during a mild infection than after vaccination. Participants with hybrid immunity due to infection plus
296	vaccination(s) had higher anti-S1 GMCs than those with infection or vaccination (one or two doses)
297	immunity only. This is also in agreement with the published literature [25, 27, 28]. Studies have
298	shown that within the hybrid immunity group, concentrations depend on the type(s) of vaccine(s)
299	used, the number of doses, and the severity of the infection [28–30].
300	
301	As we had already shown earlier, BCG vaccination administered in the beginning of the study did not

302 influence SARS-CoV-2 specific antibody concentrations approximately one year later. This is in

303 agreement with most other BCG trials conducted during the COVID-19 epidemic failing to

Version 22 January 2024

demonstrate benefits of BCG vaccination on COVID-19-related endpoints [18, 19, 31–33].

305

306	Overall infection severity was associated with M12 anti-S1 (when analysed as an indicator variable
307	but not as an ordinal variable) and anti-N GMCs (when analysed as an indicator or ordinal variable),
308	and individual symptom severity and durations with M12 anti-N GMCs only. However, the latter
309	associations did show non-statistical trends in the same direction for M12 anti-S1 GMCs. The
310	somewhat inconsistent findings for higher M12 anti-S1 GMCs with increasing infection severity could
311	be explained by the fact that this increase was non-linear, with GMCs starting out higher than anti-N
312	GMCs (likely because the host immune system is highly exposed to the viral S1-protein and less so
313	the N-protein)[3] and reaching a plateau more easily. Several other studies have reported increasing
314	anti-S1 and anti-N antibody concentrations with increasing infection severity [1, 13, 34], but some
315	studies did not find this association [35, 36]. Many of these studies, however, compared WHO-
316	defined mild, moderate and severe infections (with the latter two requiring hospitalisation). Our
317	study was conducted in a generally healthy population below the age of 65, and the detailed and
318	comprehensive diary data allowed us to also include asymptomatic infections and to subdivide the
319	WHO-defined mild category into very mild and mild subcategories. Even within this range of
320	asymptomatic to mild infections differences in impact on antibody responses were measurable.
321	
322	Our analyses did not reveal associations between M12 antibody concentrations and having had or
323	having Long COVID or long-term loss of smell/taste, but the analysis population included only 19
324	Long COVID cases. Several other studies reported weaker SARS-CoV-2-specific antibody responses
325	following an infection in Long COVID cases [37-39]. However, one study reported similar anti-S1 and
326	anti-N concentrations between fully recovered and Long COVID patients after infection but aberrant
327	immune responses in Long COVID patients following COVID-19 vaccination [40]. The potential
328	associations between immune responses and development of Long COVID requires further study.

329

330	The main strengths of the study were that we captured the entire first year of the Dutch COVID-19
331	epidemic and had detailed and comprehensive data, allowing us to identify asymptomatic infections
332	and to subdivide WHO mild infections into very mild and mild. A main limitation was that we could
333	not account for antibody waning at the individual participant level, but we think that follow-up time
334	after most immune events was too short for waning to have influenced results significantly. Other
335	limitations include the use of two different blood sampling methods (venepuncture and fingerprick
336	sampling) and the suboptimal sensitivity of the anti-N assay for detecting asymptomatic infections
337	(67%) [9]. We may therefore have missed some asymptomatic infections and overestimated the M12
338	anti-N GMC in the asymptomatic group.
339	
340	Conclusions
341	Our study confirmed that anti-S1 and anti-N GMCs were associated with overall infection severity,
342	but additionally showed that this was the case even in infections ranging from asymptomatic to mild
343	in an otherwise healthy population. Anti-S1 GMCs were also associated with numbers and types of
344	COVID-19 vaccinations, with the combination of infection and vaccination(s) eliciting the greatest
345	response. Anti-S1 and anti-N GMCs were not associated with having had of having Long COVID or
346	long-term loss of smell/taste.

347 Acknowledgments

We thank the healthcare workers for their participation, and colleagues in the UMC Utrecht and
 participating hospitals and laboratories who implemented the BCG-Corona trial during the Dutch
 COVID-19 epidemic.

351

352 Financial Support

353 The original BCG-Corona trial was not externally funded. The additional work included in this 354 publication is part of the project "BCG vaccination to minimize COVID-19 disease severity and 355 duration" with project number 10430 01 201 0026 of the research programme COVID-19 which is 356 financed by the Netherlands Organization for Health Research and Development (ZonMw). MN was 357 also funded by an ERC Advanced Grant (grant number 833247) and Spinoza grant of the Netherlands 358 Organization for Scientific Research (NWO). LV was also funded by a Hypatia Tenure Track grant of 359 the Radboud University Medical Center (Nijmegen). The funders did not have any role in the 360 collection, analysis, and interpretation of data; in the writing of the report; and in the decision to 361 submit the paper for publication.

362

363 Author contributions

364 JW, TD, MB and MN designed and obtained funding for the study. TD and JW supervised the clinical 365 data collection, and JW supervised the analyses and paper-writing. GS, RB, and FK conducted the 366 antibody testing and MJ and LV provided additional immunological expertise. JC contributed to the 367 clinical data collection, conducted the analyses, and wrote the first draft of the paper. All authors 368 read and approved the final version. JC and JW have full access to all data and take responsibility for 369 the integrity of the data and the accuracy of the data analyses.

371 Data Availability Statement

Individual participant data that underlie the results reported in this article will be made available
after deidentification to investigators whose proposed use of the data has been approved by an
independent review committee up to 5 years following publication. The study protocol will be
available to anyone during this same time frame. Information regarding submitting proposals and
accessing data may be found on https://dataverse.nl/.

377

370

378 Declaration of Conflicts of Interests

379 LV reports consulting fees from MSD in the last 36 months (unrelated to the work in this manuscript, 380 payments to institution). MB reports research grants from Janssen Vaccines, Novartis, CureVac, and 381 Merck, Advisory Board memberships of Spherecydes, Pfizer, MSD, Novartis and AstraZeneca, and 382 DSMB membership of Sanofi, in the last 36 months (unrelated to the work in this manuscript, 383 payments to institution). MN is scientific founder and scientific advisory board member of Trained 384 Therapeutix Discovery (TTxD) and scientific founder of Lemba Therapeutics, has obtained research grants from GSK Biologicals, TTxD, and Ono Pharma, and consultancy fees from TTxD. JW reports 385 386 payments for meeting attendance from the Dutch Ministry of Health and Sports and the Netherlands 387 Organization for Health Research and Development (ZonMw) in the last 36 months (unrelated to the

388 work in this manuscript, payments to institution). All other authors declare no competing interests.

References

- 1. Munitz A, et al. (2021) Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. *Scientific Reports;* **11**:3461
- 2. McAndrews KM, et al. (2020) Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. *Journal of Clinical Investigation Insight*; 5:e142386, 142386
- 3. Yang H, Rao Z (2021) Structural biology of SARS-CoV-2 and implications for therapeutic development. *Nature Reviews Microbiology;* **19**:685–700
- 4. Walsh EE, et al. (2020) Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *The New England Journal of Medicine;* **383**:2439–2450
- 5. Baden LR, et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *The New England Journal of Medicine;* **384**:403–416
- 6. Sadoff J, et al. (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. *The New England Journal of Medicine*; 384:2187–2201
- 7. Barrett JR, et al. (2021) Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. *Nature Medicine*; **27**:279–288
- 8. Solastie A, et al. (2021) A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies. *Microbiology Spectrum;* 9:e01131-21
- 9. den Hartog G, et al. (2020) SARS-CoV-2–specific antibody detection for seroepidemiology: A multiplex analysis approach accounting for accurate seroprevalence. *The Journal of Infectious Diseases*; **222**:1452–1461
- 10. van den Hoogen LL, et al. (2022) Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination? *Vaccine*; **40**:2251–2257
- 11. Tilocca B, et al. (2020) Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. *Microbes and Infection*; **22**:188–194
- 12. Tan Y-J, et al. (2004) Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. *Clinical and Diagnostic Laboratory Immunology*; **11**:362–371
- 13. Cervia C, et al. (2021) Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. *Journal of Allergy and Clinical Immunology*; **147**:545-557.e9
- 14. Lou B, et al. (2020) Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. European Respiratory Journal; 2000763
- 15. Zervou FN et al. (2021) SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. *Journal of Medical Virology*; **93**:5409–5415

- 16. Wölfel R, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. *Nature* 581:465–469
- 17. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. (2020) A minimal common outcome measure set for COVID-19 clinical research. *The Lancet Infectious Diseases*; **20**:e192–e197
- Ten Doesschate T, et al. (2022) Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. *Clinical Microbiology and Infection*; 28:1278–1285
- 19. **Claus J, et al.** (2023) BCG vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial. *mBio*. https://doi.org/10.1128/mbio.00356-23
- 20. **ten Doesschate T, et al.** (2020) Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials. *Trials;* **21**:481
- 21. World Health Organization (2020) First WHO international standard for anti-SARS-CoV-2 immunoglobulin (human).
- 22. Vos ERA, et al. (2021) Associations between measures of social distancing and severe acute respiratory syndrome coronavirus 2 seropositivity: A nationwide population-based study in the Netherlands. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*; **73**:2318–2321
- 23. **van den Hoogen LL, et al.** (2022) SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics. *Scientific Reports;* **12**:5935
- 24. Wei J, et al. (2021) Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nature Microbiology;* **6**:1140–1149
- Eyre DW, et al. (2021) Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status. *Clinical Microbiology and Infection*; 27:1516.e7-1516.e14
- 26. **Pooley N, et al.** (2023) Durability of vaccine-induced and natural immunity against COVID-19: A narrative review. *Infectious Diseases and Therapy*; **12**:367–387
- 27. Hall V, et al. (2022) Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. *The New England Journal of Medicine*; NEJMoa2118691
- 28. **Bobrovitz N, et al.** (2023) Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. *The Lancet Infectious Diseases*; **23**:556–567
- 29. Legros V, et al. (2021) A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. *Cellular and Molecular Immunology*; **18**:318–327

- 30. **Shrotri M, et al.** (2021) Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. *Lancet*; **398**:385–387
- 31. **Koekenbier EL, et al.** (2023) Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. *Clinical Microbiology and Infection*; **29**:781–788
- 32. **Moorlag SJCFM, et al.** (2022) Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America;* **75**:e938–e946
- 33. **Pittet LF, et al.** (2023) Randomized trial of BCG vaccine to protect against Covid-19 in health care workers. *The New England Journal of Medicine*; **388**:1582–1596
- 34. **Patil HP, et al.** (2021) Antibody (IgA, IgG, and IgG subtype) responses to SARS-CoV-2 in severe and nonsevere COVID-19 patients. *Viral Immunology*; **34**:201–209
- 35. **To KK-W, et al.** (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*; **20**:565–574
- 36. **Takita M, et al.** (2022) Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. Scientific Reports; **12**:9147
- 37. García-Abellán J, et al. (2021) Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. *Journal of Clinical Immunology*; **41**:1490–1501
- 38. **Cervia C, et al.** (2022) Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. *Nature Communications*; **13**:446
- 39. Augustin M, et al. (2021) Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *The Lancet Regional Health-Europe*; **6**:100122
- 40. Joung S, et al. (2023) Serological response to vaccination in post-acute sequelae of COVID. BMC Infectious Diseases; 23:97

Figure 1: Population and study flow



Participants who did not have evidence of a SARS-CoV-2 infection and less than 80% diary app completion (n=166) were excluded because the probability of having missed infections in that group is high. We also excluded participants with inconclusive serology at M12 (n=36, sero converted for anti-N but not anti-S1) and those who did not donate a blood sample at M12 (n=206): 114 in the BCG group and 92 in the placebo group (p=0.237). The 4 participants who reported more than one infection during follow-up (two infections in all cases) were excluded because that group was too small to generate meaningful results. In the main analyses, the seroconversion window was considered to be from 14 days before the M12 sampling date until the date of sampling; in sensitivity analyses, we also considered sero onversion windows of 7 and 0 days (Supplementary Methods and Results).



Figure 2: M12 anti-S1 and anti-N log₁₀ concentrations by number and type of immune events



Abbreviations: BCG=Bacillus Calmette-Guérin vaccine; Inf=infection; Inf+Vac1=infection and one dose of a COVID-19 vaccine; Inf+Vac2=infection and two doses of a COVID-19 vaccine; Vac1=one dose of a COVID-19 vaccine; Vac2=two doses of a COVID-19 vaccine. Kruskal-Wallis for overall statistical testing of mean log₁₀ transformed M12 antibody concentrations and Wilcoxon sum rank test for within group.

A-B: Analysis population: denominator N=970. The green point range indicates the mean and standard deviation.

C-F: Analysis population: denominator N=970. The point range shows the mean and standard deviation.

G-I: Participants with an infection were excluded; denominator N=747.

J-M: Only participants with an infection included: denominator N=199; 24/223 participants with unknown severity were excluded. The point range indicates the mean and standard deviation.

A. Baseline characteristics	Analysis population				Randomised population		
Cells contain n (% of N) unless stated otherwise	Placebo	BCG	p ^{1,2}	Overall	Overall	p ^{1,3}	
	N =480	N=490		N=970	N=1,511		
Age in years, mean (SD)	43.0 (12.6)	42.0 (12.6)	0.208	42.5 (12.6)	42.0 (12.7)	0.366	
Female	355 (74.0)	369 (72.3)	0.683	724 (74.7)	1122 (74.3)	0.868	
Smoking status Current	31 (6.5)	34 (6.9)	0.143	65 (6.7)	123 (8.1)	0.258	
Former	136 (28.3)	166 (33.9)		302 (31.1)	436 (28.9)		
Never 4	313 (65.2)	290 (59.2)	0.026	603 (62.2)	952 (63.0)	0.400	
Work-related exposure Low	72 (15.0)	76 (15.5)	0.936	148 (15.3)	213 (14.1)	0.492	
High	121 (25.2)	295 (60.2)		240 (24.7)	942 (62 3)		
History of BCG vaccination	83 (17 3)	91 (18.6)	0.663	174 (17.9)	256 (16.9)	0.559	
Past TP test results ⁵ Tested perative	220 (66 7)	31 (18.0)	0.003	640 (66 0)	1016 (67.2)	0.333	
Tested nositive	49 (10 2)	45 (9 2)	0.135	94 (97)	136 (90)	0.491	
Never tested	109 (22 7)	115 (23 5)		224 (23.1)	347 (23.0)		
Unknown	2 (0.4)	10 (2.0)		12 (1.2)	12 (0.8)		
Respiratory infection in winter 2019-2020	_ ()	()	0.310	(0 748	
No	349 (72,7)	364 (74.3)		713 (73.5)	1090 (72.1)		
Yes, with fever	35 (7.3)	44 (9.0)		79 (8.1)	127 (8.4)		
Yes, without fever	96 (20.0)	82 (16.7)		178 (18.3)	294 (19.5)		
Influenza vaccination in winter 2020-2021 ⁶			0.239		· · ·	<0.001	
Yes	273 (56.9)	255 (52.0)		528 (54.4)	697 (46.1)		
Νο	142 (29.6)	169 (34.5)		311 (32.1)	428 (28.3)		
Missing	65 (13.5)	66 (13.5)		131(13.5)	386 (25.5)		
Influenza vaccination prior to follow-up	278 (57.9)	282 (57.6)	0.960	560 (57.7)	872 (57.7)	1.000	
Any other vaccination in past year ⁷	51 (10.6)	54 (11.0)	0.924	105 (10.8)	162 (10.7)	0.988	
Current use of anti-hypertensive medication	33 (6.9)	28 (5.7)	0.540	61(6.3)	99 (6.6)	0.860	
History of cardiovascular disease	14 (2.9)	9(1.8)	0.371	23 (2.4)	34 (2,3)	0.953	
Current use of anti-diabetic medication	2 (0.4)	3 (0.6)	1.000	5 (0.5)	9 (0.6)	1.000	
History of asthma	35 (7 3)	34 (6 9)	0.929	69(71)	101 (6 7)	0 740	
History of bay fever	130 (27 1)	158 (32 2)	0.091	288 (29 7)	441 (29.2)	0.823	
History of other nulmonary disease	12 (2 5)	11 (2 2)	0.960	23 (2.4)	32 (2 1)	0.781	
Any lung disease (provides three combined)	154 (22.3)	175 (25 7)	0.360	23 (2.4)	407 (22.0)	0.701	
Any lung disease (previous three combined)	Analysis population			529 (55.9)	497 (32.9)	0.020	
B. Immune events	Analysis population Randomised p				Kandomised pop	1,3	
Cells contain n (% of N) unless stated otherwise	Placebo	BCG	р	Overall N=070	Overall	р	
#1	N= 480	N=430	0 222	452 (467)	(70 (40 0)	<0.001	
# Immune events 0	218 (45.4)	235 (48.0)	0.323	40.7)	679 (46.0)	<0.001	
1	127 (26 5)	133 (27 1)		260 (26.8)	216 (14 6)		
2	42 (8.8)	28 (5 7)		70 (7 2)	94 (6 4)		
Immune event type None	218 (45.4)	235 (48.0)	0.614	453 (46 7)	680 (45.0)	<0.001	
Infection ⁹	62 (12 9)	61 (12.4)	0.011	123 (12.7)	158 (10.5)	101001	
Vaccine 1 dose	31 (6.5)	33 (6.7)		64 (6,6)	177 (11.7)		
Vaccine 2 doses	112 (23.3)	118 (24.1)		230 (23.7)	320 (21.2)		
Infection + 1 dose	15 (3.1)	15 (3.1)		30 (3.1)	54 (3.6)		
Infection + 2 doses	42 (8.8)	28 (5.7)		70 (7.2)	86 (5.7)		
COVID-19 vaccine product and dose ¹⁰			0.148			0.002	
None	280 (58.3)	296 (60.4)		576 (59.4)	868 (57.4)		
mRNA 1 dose	30 (6.2)	25 (5.1)		55 (5.7)	125 (8.3)		
mRNA 2 doses	154 (32.1)	146 (29.8)		300 (30.9)	416 (27.5)		
Vector 1 dose	13 (2.7)	23 (4.7)		36 (3.7)	86 (5.7)		
Vector 2 doses	0 (0.0)	(0.0)		(0.0)	7 (0.5)		
Unknown 1 dose	3 (0.6)	0 (0.0)		3 (0.3)	9 (0.6)		
Had SARS-CoV-2 infection during follow-up ¹¹	119 (24.8)	104 (21.2)	0.214	223 (21.2)	298 (19.7)	0.109	
Intection severity No infection	361 (75.2)	386 (78.8)	0.727	747 (77.0)	1213 (77.9)	0.541	
Asymptomatic	15 (3.1)	18 (3.7)		33 (3.4)	42 (2.8)		
Very Mild	65 (13.5)	55 (11.2)		120 (12.4)	163 (10.8)		
Nilla Madarata	25 (5.2)	1 (0.2)		44 (4.5)	3 (0.2)		
Woderale	13 (2.2)	11 (0.2)		2 (0.2)	29 (1 Q)		
Acute duration of infection ¹³	13 (2.7)	II (Z.Z)	0.401	24(2.3)	25 (1.9)	0 000	
Acute duration of meetion O days/no infection	377 / 78 51	405 (82 7)	0.401	782 (80 6)	1251 (82.8)	0.908	
0 days/10 mectoli 0-1 weeks	20 (4 2)	9(1.8)	1	29 (3 0)	44 (2 9)		
1- 2 weeks	22 (4.6)	23 (4.7)		45 (4.6)	61 (4.0)		
2-3 weeks	17 (3.5)	15 (3.1)		32 (3.3)	42 (2.8)		

Table 1: Participant baseline characteristics and immune events during follow-up

3-4 weeks		9 (1.9)	8 (1.6)		17 (1.8)	20 (1.3)	
4+ weeks		10 (2.1)	5 (1.0)		15 (1.5)	18 (1.2)	
Lingering		10 (2.1)	12 (2.4)		22 (2.3)	34 (2.3)	
Ongoing/UNK		15 (3.1)	13 (2.7)		28 (2.9)	41 (2.7)	
Long COVID	No	106 (89.1)	87 (83.7)	0.489	193 (86.5)	256 (85.9)	0.975
	Yes	8 (6.7)	11 (10.6)		19 (8.5)	27 (5.0)	
	Unknown	5 (4.2)	6 (5.8)		11 (4.9)	15 (9.1)	
Long term loss of smell/taste No		112 (94.1)	99 (95.2)	0.208	211 (94.6)	278 (93.3)	0.711
	Yes	5 (4.2)	1(1.0)		6 (2.7)	12 (4.0)	
	Unknown	2 (1.7)	4 (3.8)		6 (2.7)	8 (2.7)	

Abbreviations: BCG=Bacillus Calmette-Guérin vaccine; M=month; SD=standard deviation; TB=tuberculosis.

1. Chi-squared tests for categorical variables and Wilcoxon rank sum test for continuous variables.

2. Statistical test comparing baseline characteristics between the BCG and placebo group in the analysis population.

- Statistical test comparing baseline characteristics between the analysis (N=970) and randomised populations (N=1,511).
 Work related exposure is a combination of participants expected to work in a COVID-19 ward and the percentage of work hours with direct patient contact (Supplementary Methods).
- 5. Tuberculosis tests include the Mantoux and/or TB QuantiFERON tests. A person who tested positive could have tested positive on either or both tests.
- 6. Only the missing category is statistically significantly different between the randomised and analysis populations.
- 7. Includes DTaP-IPV, hepatitis A, hepatitis B, yellow fever, typhoid, rabies, mumps-measles-rubella, meningococcal, pneumococcal, *Haemophilus influenza* type B, Ebola, tick-borne encephalitis, human papillomavirus, and unknown.
- 8. An immune event is considered to be either one natural infection or one dose of a COVID-19 vaccine.
- 9. No-one in the analysis population, and four persons in the randomised population, experienced more than one infection (two each).
- 10. COVID-19 vaccines available in the Netherlands during the study period are listed in the methods. In addition, one person received an experimental mRNA vaccine by CureVac N.V. in a clinical trial setting. That vaccine was never marketed due to insufficient efficacy, but the person was included in the mRNA vaccines group.
- 11. A natural infection was defined as a reported positive test (by the participants through the diary app) or identified by serology (evidence of anti-S1 at sampling round 1 or both anti-S1 and anti-N at sampling round 2). None of the participants in the analysis population reported a positive PCR test prior to follow-up at baseline.
- 12. Participants with an unsure infection status at M 12 (never reported a positive test and/or seropositive for anti-N but not anti-S 1 at M12; n=36) were considered as never having had an infection during follow-up in the randomised population and were removed from the analysis population.
- 13. Participants who never had an infection during follow-up are included in the 0 days/no infection category.

Cells contain mean (SD)		M12 a nti-S1			M12 anti-N		
		Log ₁₀ conc	GMC ¹	p²	Log ₁₀ conc	GMC ¹	p²
Overall mean		1 55 (1 39)	35 /8 (2/ 55)		0.73 (0.52)	(10/ml) 5 37 (3 3 1)	
Intervention	BCG	1.55(1.55)	32 36 (22 91)	0.431	0.73 (0.52)	5.13 (3.38)	0.096
intervention	Placebo	1.51(1.50) 1.59(1.41)	38.90 (25.70)	0.451	0.71(0.53)	5.62 (3.31)	0.050
Immune event ³	0	0.25(0.32)	1 78 (2 09)	<0.001	0.73 (0.32)	3.47 (1.91)	<0.001
initialie event	1	2.02 (0.86)	104 71 (7 24)	10.001	1 12 (0 70)	13 18 (5 01)	10.001
	2	2.02 (0.00)	954 99 (4 07)		0.65(0.47)	4 47 (2 95)	
	3	3 36 (0.42)	2290 87 (2.63)		1 28 (0 51)	19.05 (3.23)	
Immunity type	None	0.25 (0.32)	1 78 (2 09)	<0.001	0.54 (0.28)	3 47 (1 91)	<0.001
initiality type	Infection only ⁴	1 90 (0.82)	79.43 (6.61)	10,001	1 42 (0 65)	26 30 (4 4 7)	10.001
	Vaccine 1 dose	2 25 (0.88)	177 83 (7 59)		0.53 (0.26)	3 39 (1 82)	
	Vaccine 2 doses	2.25 (0.56)	794 33 (3 47)		0.55 (0.26)	3 47 (1 82)	
	Infection + 1 dose	3.60 (0.73)	3981.07 (5.37)		1.50 (0.75)	31.62 (5.62)	
	Infection + 2 doses	3 36 (0 42)	2290 87 (2.63)		1 28 (0 51)	19.05 (3.24)	
COVID-19 vaccine r	product and dose ⁵	0.00(0.12)	2200107 (2100)	< 0.001	1120 (01012)	10100 (012 1)	0 956
	None	0.25 (0.32)	1 78 (2 09)		0.54 (0.28)	3 47 (1 91)	0.000
	mBNA 1 dose	2 67 (0 76)	467 73 (5 75)		0.56 (0.28)	3 36 (1 91)	
	mRNA 2 doses	2 90 (0 54)	794 33 (3 47)		0.54 (0.26)	3 47 (1 82)	
	Vector 1 dose	1 80 (0 70)	63 10 (5 01)		0.51 (0.23)	3 24 (1 70)	
Infection severity ⁶	Asymptomatic	2 54 (0 90)	346 74 (7 94)	0.566	1 14 (0 49)	13 80 (3 09)	0.002
incetion severity	Very mild	2.52 (1.03)	331 13 (10 72)	0.500	1 36 (0 66)	22 91 (4 57)	0.002
	Mild	2.52 (1.03)	467 73 (13 49)		1.50 (0.50)	44 67 (3 31)	
	Moderate	3 36 (0 56)	2290 87 (3 63)		1.66(1.41)	45 71 (25 70)	
Acute enisode dura	ution ⁷		2200107 (01007)	0.755	1.00 (1.11)	1017 2 (20170)	0.128
Acute episode dula	0 days/no infection	2 53 (0 92)	33 84 (8 32)	0.755	1 13 (0 48)	13 49 (3 02)	0.120
	0-1 weeks	2.55 (0.52)	281 84 (12 88)		1 37 (0 65)	23 44 (4 47)	
	1-2 weeks	2 49 (1 04)	309.03 (10.96)		1 32 (0 64)	20 89 (4 37)	
	2-3 weeks	2 80 (0 91)	630 96 (8 13)		156 (0.69)	36 31 (4 90)	
	3-4 weeks	2.38(0.97)	239.88 (9.33)		1.37 (0.67)	23.44 (4.68)	
	4+ weeks	2.61(1.28)	407.38 (19.05)		1.57 (0.53)	37.15 (3.39)	
	Lingering	2.80(1.07)	630.96 (11.75)		1.49 (0.62)	30.90 (4.17)	
	Ongoing/UNK	2.63 (1.22)	426.58 (16.60)		1.46 (0.66)	28.84 (4.57)	
Long COVID ^{7,8}	No	2.59(1.03)	389.05 (10.72)	0.973	1.36 (0.63)	22.91 (4.27)	0.194
5	Yes	2.57 (1.25)	371.54 (17.78)		1.53 (0.66)	33.88 (4.57)	
Unknown		2.55 (1.07)	354.81 (11.75)		1.63 (0.54)	42.66 (3.47)	
LT loss taste/smell ⁷	^{/,9} No	2.57 (1.04)	371.54 (10.96)	0.572	1.38 (0.63)	23.99 (4.27)	0.541
	Yes	3.06 (1.11)	1148.15 (12.88)		1.30 (0.49)	19.95 (3.09)	
	Unknown	2.56(1.25)	363.08 (17.78)		1.62 (0.74)	41.69 (5.50)	
Dyspnea severity ^{10,}	¹¹ 0	2.57 (1.07)	371.54 (11.75)	0.938	1.35 (0.61)	22.39 (4.07)	0.239
	1-3	2.63 (0.99)	426.58 (9.77)		1.42 (0.68)	26.30 (4.79)	
	4-5	2.55 (0.99)	354.81 (9.77)		1.54 (0.60)	34.67 (3.98)	
Dyspnea duration (days) ¹¹ 0	2.59(1.08)	389.05 (12.02)	0.373	1.36 (0.62)	22.91 (4.17)	0.280
	1-3	2.72 (0.94)	524.81 (8.71)		1.28 (0.58)	19.05 (3.80)	
	4-7	2.32 (0.96)	208.93 (9.12)		1.38 (0.73)	23.99 (5.37)	
	Week+	2.84 (0.94)	691.83 (8.71)		1.62 (0.54)	41.69 (3.47)	
Resp symptoms sev	verity ^{10,12,13} 0	2.48 (0.97)	302.00 (9.33)	0.240	1.12 (0.55)	13.18 (3.55)	0.003
	1-3	2.42 (1.11)	263.03 (12.88)		1.38 (0.65)	23.99 (4.47)	
	4-5	2.73 (0.97)	537.03 (9.33)		1.54 (0.61)	34.67 (4.07)	
Resp symptoms du	ration (days) ^{12,14} 0	2.46 (0.96)	288.40 (9.12)	0.641	1.12 (0.55)	13.18 (3.55)	0.006
	1-3	2.56(1.13)	363.08 (13.49)		1.42 (0.62)	26.30 (4.17)	
	4-7	2.37 (1.15)	234.42 (14.13)		1.29 (0.68)	19.50 (4.79)	
Week+		2.65 (1.02)	446.68 (10.47)		1.52 (0.62)	33.11 (4.17)	
Fever ^{10,15} No		2.57 (1.06)	371.54 (11.48)	0.845	1.31 (0.61)	20.42 (4.07)	0.029
Yes		2.60(1.01)	398.11(10.23)		1.50 (0.63)	31.62 (4.27)	
Fever duration (day	ys) ^{10,15} O	2.57 (1.06)	371.54 (11.48)	0.781	1.31 (0.61)	20.42 (4.07)	0.024
	1-3	2.63 (1.09)	426.58 (12.03)		1.29 (0.53)	19.50 (3.39)	
	4-7	2.48 (0.93)	302.00 (8.51)		1.51 (0.68)	32.36 (4.79)	
	Week+	2.74 (1.07)	549.54 (11.75)		1.69 (0.60)	48.98 (3.98)	
Non-resp symptom	s severity ^{10,16,17} 0	2.35 (1.07)	223.87 (11.75)	0.225	1.13 (0.54)	13.48 (3.47)	0.002
	1-3	2.73 (0.95)	537.03 (8.91)		1.38 (0.59)	23.99 (3.89)	
	4-5	2.55 (1.05)	354.81 (11.22)		1 50 (0.65)	31.62 (4.47)	

Table 2: M12 anti-S1 and anti-N geometric mean concentrations by numbers and types of immune events

Abbreviations: BCG=Bacillus Calmette-Guerin; conc=concentration; GMC=geometric mean concentration; |U=International units; LT=long-term; M=Month; resp=respiratory; SD=standard deviation.

- 1. Antilog 10^x of the log10 transformed mean concentration.
- $2. \qquad {\rm Kruskal-Wallis} \ {\rm p-values} \ {\rm for \ comparisons} \ {\rm of \ mean} \ {\rm log_{10}} \ {\rm transformed \ concentrations} \ {\rm in \ } U/m \ {\rm after \ adding \ a \ pseudo-count \ of \ 1.}$
- One immune event (N=187): 123 (65.8%) had an infection and 64 (34.2%) received one dose of a COVID-19 vaccine. Two immune events (N=260): 30 (11.5%) had an infection and received one dose of a COVID-19 vaccine, while 230 (88.5%) received two doses of a COVID-19 vaccine. All participants with three immune events (N=70) had an infection and received two COVID-19 vaccine doses.
- 4. No-one in this dataset experienced more than one infection.
- 5. Denominator is 747 because participants with infections were excluded as well as an additional participant due to missing vaccine type. The number of COVID-19 vaccine doses was calculated as the total number of doses received by the participant during follow-up regardless of whether the primary vaccination series consisted of one or two doses. The COVID-19 vaccines available during the study period in the Netherlands are listed in the methods.
- 6. Denominator is 199 because only participants who experienced an infection were included and 24 participants with unknown infection severity were removed. We also performed Jonckheere's tests for trend with an *a priori* ordering of infection severity for mean anti-S 1 log₁₀-transformed concentrations (p-value=0.367) and mean anti-N log₁₀-transformed concentrations (p-value=0.001).
- 7. Denominator is 223 because only participants who experienced an infection were included.
- 8. Long COVID was defined as continuing to report symptoms other than standalone loss of smell/taste for at least 60 days after the end of the acute infection episode. "Unknown" includes participants who were reporting symptoms past the end of acute infection episode but had not yet reached 60 days at the time the diary app was discontinued. There were 23 cases but 4 were excluded from the analysis population for being in the seroconversion window of the first COVID-19 vaccine dose. Of the remaining 19 cases, 5 had the infection in the first period and 14 in the second period; 8 received at least one COVID-19 vaccine dose in the first period and 11 were never vaccinated.
- 9. Long-term loss of smell/taste was defined as continuing to report standalone loss of smell/taste for at least 60 days after the end of the acute infection episode. "Unknown" includes participants who were reporting loss of smell/taste past the end of acute infection episode but had not reached 60 days at the time the diary app was discontinued. There were 9 cases but three were excluded from the analysis population for being in the seroconversion window of the first COVID-19 vaccine dose. When excluding the unknown category from the analysis, p=0.290.
- 10. Symptoms were reported on a scale of 0-5: 0 for not present and 1-5 present with increasing severity. Fever was reported as present or not and was defined as having a temperature above 38°C.
- 11. Denominator is 218 because only participants who experienced an infection were included and 5 additional participants were removed due to unknown dyspnea severity and/or duration.
- 12. Respiratory symptoms exclude dysphoea. Most participants reported more than one type of respiratory symptom during an infection episode; we took the highest severity reported for any respiratory symptom. The duration was calculated from the day on which the first respiratory symptom was reported until the day a respiratory symptom was reported.
- 13. Denominator is 205 because only participants who experienced an infection were included and 18 additional participants were removed due to unknown respiratory symptom severity.
- 14. Denominator is 200 because only participants who experienced an infection were included and 23 additional participants were removed due to unknown or ongoing respiratory symptom duration.
- 15. Denominator is 217 because only participants who experienced an infection were included and 6 additional participants were removed due to unknown presence of fever or unknown fever duration.
- 16. Non-respiratory symptoms exclude fever. Most participants reported more than one type of non-respiratory symptom during an infection episode; we took the highest severity reported for any non-respiratory symptom. The duration was calculated from the day on which the first non-respiratory symptom was reported until the last day a non-respiratory symptom was reported.
- 17. Denominator is 205 because only participants who experienced an infection were included and 18 additional participants were removed due to unknown non-respiratory symptom severity.

	Covariate	Estimate; (95% CI)	Exp ⁴ (estimate); (95% CI)	р	VIF⁵		
12 Anti-S1 ^{6,7}	Model intercept ¹	0.50; (0.36, 0.64)	3.02; (2.19, 4.17)	<0.001			
	BCG vs placebo ²	0.02; (-0.05, 0.09)	1.05; (0.89, 1.23)	0.585	1.01	BCG vs Placebo	
	Age (per year)	-0.004; (-0.01, -0.007)	0.99; (0.98, 0.99)	0.008	1.04	Age	
	Male sex	-0.04; (-0.12, 0.04)	0.91; (0.76, 1.10)	0.311	1.01	Male vs Female	
	All the below compared to participants who never had an infection or vaccination					Asymptomatic infection	
	during follow-up:					Very mild infection	
	Asymptomatic	1.14; (0.95, 1.34)	14.13; (8.91, 21.88)	<0.001	1.01	Mild infection	-
Σ	Very mild	1.19; (1.08, 1.30)	16.22; (12.59, 20.42)	<0.001	1.02	Moderate infection	
<u>e</u> ::	Mild	1.39; (1.22, 1.56)	25 12; (16 98, 38 02)	<0.001	1.02	Unknown severity	-
ро	Moderate	1.89 (1.12, 2.66)	74.13; (12.30, 446.68)	<0.001	1.01	mRNA vaccine 1 dose	-
Σ	Unknown severity	1.01; (0.78, 1.24)	10.96; (6.46, 18.62)	<0.001	1.02	mRNA vaccine 2 doses	•
	mRNA 1 dose	2.31; (2.15, 2.46)	112.20; (47.86, 263.03)	<0.001	1.06	Vector vaccine 1 dose	-
	mRNA 2 doses	2.40; (2.32, 2.47)	245.47; (204.17, 295.12)	<0.001	1.06	0	1 2
	Vector 1 dose	1.49; (1.31, 1.68)	223.87; (151.36, 331.13)	<0.001	1.06		Estimate
	Covariate	Estimate (95% CI)	Exp ⁴ (estimate)	р	VIF⁵		
	Model intercept ³	0.48; (0.39, 0.57)	2.95; (2.40, 3.63)	<0.001		BCG vs Placebo	
6,8	BCG vs placebo ²	-0.003; (-0.05, 0.04)	0.99; (0.89, 1.10)	0.901	1.01	000 131 140000	I
۳z	Age (per year)	0.001; (-0.007, 0.003)	1.00; (0.98, 1.01)	0.312	1.06	Age	
Anti	Male sex	0.06; (0.005, 0.11)	1.15; (1.01, 1.29)	0.040	1.01	Male vs Female	
	Hypertension med	0.06; (-0.04, 0.16)	1.15; (0.91, 1.44)	0.222	1.07	Use of anti-hypertensive medication	•
12	All the below compared to participants who never had an infection or vaccination					Asymptomatic infection	
Model: M	during follow-up:					Very mild infection	•
	Asymptomatic	0.60; (0.47, 0.74)	4.07; (2.95, 5.50)	<0.001	1.01	Mild infection	-
	Very mild	0.82; (0.74, 0.89)	6.61; (5.62, 7.94)	<0.001	1.04	Moderate infection	
	Mild	1.11; (1.00, 1.23)	13.18; (10.0, 16.98)	<0.001	1.01	Unknown severity	-
	Moderate	1.11; (0.58, 1.63)	13.48; (4.07, 45.71)	<0.001	1.01		0.0 0.5 1.0 1.5
	Unknown severity	0.86; (0.71, 1.02)	7.24; (5.13, 10.23)	<0.001	1.01		Estimate

Table 3: Multivariable models with M12 anti-S1 and anti-N log₁₀ concentrations as outcome

Abbreviations: BCG=Bacillus Calmette-Guérin vaccine; CI=Confidence Interval; M=month; VIF= Variance of Inflation Factor.

Indicator variables were created, and model building is described in more detail in supplementary methods.

1. The reference is an individual in the placebo group, zero years old, who never had a SARS-CoV2 infection and was never vaccinated for COVID-19.

2. Baseline BCG or placebo vaccination was forced into the models to take the original randomisation into account. Age and sex were forced into the models because of their well-documented effects on immune responses.

3. The reference is a female individual in the placebo group, zero years old, who never experienced a SARS-CoV-2 infection.

4. Antilog 10^x of the model estimates.

5. The VIF values for this model are all less than 5, which means that there was no evidence of multicollinearity.

6. The model includes N=967 participants (three participants with unknown vaccine types dropped out of the model).

7. Therefore, the linear equation is: Log₁₀(anti-S1 concentration M12) = 0.50 + 0.02*BCG + 1.14*Asymptomatic infection + 1.19*Very mild infection + 1.39* Mild infection + 1.89* Moderate infection+ 1.01*infection with unknown severity + 2.31*One dose of mRNA + 2.40*Two doses of mRNA + 1.49*One dose of vector -0.004*per year of age -0.04*Male.

8. The model includes N=970 participants.

9. Therefore, the linear equation is: Log₁₀(anti-N concentration M12) = 0.48 - 0.003*BCG + 0.60*Asymptomatic Infection + 0.82*Very mild infection + 1.11*Mild infection + 1.11*Moderate infection + 0.86*Infection with unknown severity + 0.06*Male + 0.001*per year of age + 0.06*Use of anti-hypertensive medication.